Total: $192.76M | ||||
Company |
Location |
Date |
Amt. (M) |
Details |
Altacor |
Cambridge, UK |
2/9 |
£1.9 ($3.1) |
Closed a second $3.1M tranche of a $5.4M equity fund raising led by Clive Austin of NVM Private Equity and including Enterprise Ventures' RisingStars Growth Fund and Beringea |
Cellerix SA |
Tres Cantos, Spain |
2/28 |
€18 ($24.8) |
Cellerix raised $24.8M in a financing completed just before the announcement of its merger agreement with TiGenix NV |
Chimerix Inc. |
Durham, N.C. |
2/15 |
$45 |
Chimerix raised $45M in a Series F financing led by New Leaf Venture Partners; other investors were Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Co., Frazier Healthcare, Pappas Ventures and Morningside Group |
Conatus Pharmaceuticals Inc. |
San Diego |
2/14 |
$20 |
Conatus raised $20M in a Series B financing led by AgeChem Venture Fund and including Aberdare Ventures, Advent Venture Partners, Bay City Capital, Bilde Healthcare Partners and Roche Venture Fund |
Diartis Pharmaceuticals Inc. |
Mountain View, Calif. |
2/22 |
ND |
Diartis raised an undisclosed amount in a Series A round from Index Ventures, Amunix Inc. and private investors |
Eviagenics |
Paris |
2/10 |
€1.3 ($1.8) |
Eviagenics closed a Series A round raising $1.8M |
Ocular Therapeutix Inc. |
Bedford, Mass. |
2/4 |
$14 |
Ocular raised $14M in a Series D round led by Ascension Health Ventures, with participation by Polaris Ventures, SV Life Sciences and Versant Ventures |
Scil Proteins GmbH |
Halle, Germany |
2/3 |
€24 ($33.1) |
Scil raised $33.1M in a financing round with BioNet Holding GmbH |
SironRX Therapeutics Inc. |
Cleveland |
2/9 |
$0.5 |
SironRX secured a combined investment commitment of $500,000 from JumpStart Ventures and the Cleveland Clinic |
SymBio Pharmaceuticals Ltd. |
Tokyo |
2/28 |
$24 |
SymBio completed a $24M Series E round led by existing shareholders Cephalon Inc. and JAFCO Co. Ltd. |
to-BBB Holding BV |
Leiden, the Netherlands |
2/4 |
€4 ($5.46) |
to-BBB closed its Series B round with investors Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corp.; existing investors Aescap Venture and Antea Participaties also participated |
Versartis Inc. |
Mountain View, Calif. |
2/17 |
$21 |
Versartis raised $21M in a Series B round |
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International. The date indicated refers to the BioWorld Today issue in which the news item can be found. ND = Not disclosed. |